NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 129 filers reported holding NURIX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,809 | -21.3% | 357,287 | 0.0% | 0.01% | -25.0% |
| Q2 2023 | $3,569 | +12.5% | 357,287 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $3,173 | -19.1% | 357,287 | 0.0% | 0.01% | -20.0% |
| Q4 2022 | $3,923 | -99.9% | 357,287 | 0.0% | 0.01% | -16.7% |
| Q3 2022 | $4,655,000 | +20.5% | 357,287 | +17.1% | 0.01% | +20.0% |
| Q2 2022 | $3,864,000 | -9.6% | 305,013 | 0.0% | 0.01% | +11.1% |
| Q1 2022 | $4,274,000 | -51.6% | 305,013 | +0.1% | 0.01% | -50.0% |
| Q4 2021 | $8,823,000 | -10.4% | 304,762 | -7.3% | 0.02% | -14.3% |
| Q3 2021 | $9,845,000 | +21.8% | 328,619 | +7.8% | 0.02% | +16.7% |
| Q2 2021 | $8,085,000 | -14.7% | 304,762 | 0.0% | 0.02% | -21.7% |
| Q1 2021 | $9,475,000 | – | 304,762 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |